![](/img/cover-not-exists.png)
616OPertuzumab (P) + trastuzumab (H) + chemotherapy (CT) for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (mGC/GEJC): Final analysis of a Phase III study (JACOB)
Tabernero, J., Hoff, P.M., Shen, L., Ohtsu, A., Shah, M.A., Cheng, K., Song, C., Wu, H., Eng-Wong, J., Kang, Y-K.Volume:
28
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx369
Date:
September, 2017
File:
PDF, 73 KB
english, 2017